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Background: Barrett’s oesophagus (BO) predisposes to oesophageal adenocarcinoma. Epidemiological
data suggest that the incidence of BO is rising but it is unclear whether this reflects a true rise in incidence
of BO or an increase in detection secondary to more upper gastrointestinal endoscopies performed. This
study aimed to examine the changes in BO incidence relative to the number of upper gastrointestinal
endoscopies performed in the general population.
Methods: We conducted a cohort study using the Integrated Primary Care Information database. This
general practice research database contains the complete and longitudinal electronic medical records of
more than 500 000 persons.
Results: In total, 260 incident cases of BO were identified during the study period. The incidence of BO
increased from 14.3/100 000 person years in 1997 (95% confidence interval (CI) 8.6–22.4) to 23.1/
100 000 person years (95% CI 17.2–30.6) in 2002 (r2 = 0.87). The number of upper gastrointestinal
endoscopies decreased from 7.2/1000 person years (95% CI 6.7–7.7) to 5.7/1000 person years (95% CI
5.4–6.1) over the same time period. This resulted in an overall increase in detected BO per 1000
endoscopies from 19.8 (95% CI 12.0–31.0) in 1997 to 40.5 (95% CI 30.0–53.5) in 2002 (r2 = 0.93). The
incidence of adenocarcinoma increased from 1.7/100 000 person years (95% CI 0.3–5.4) in 1997 to
6.0/100 000 person years (95% CI 3.3–10.2) in 2002 (r2 = 0.87).
Conclusion: The incidence of diagnosed BO is increasing, independent of the number of upper
gastrointestinal endoscopies that are being performed. This increase in BO incidence will likely result in a
further increase in the incidence of oesophageal adenocarcinomas in the near future.
T
he incidence of adenocarcinoma of the oesophagus (AC)
has increased dramatically since the 1970s, at a rate
faster than any other type of cancer.1–3 Since the 1980s
the incidence has been rising by 4–10% annually, and
presently this increasing trend is still continuing.4 5 The
cause of the ongoing increase is unknown. Suggested
explanations include an increase in the prevalence of risk
factors such as smoking and obesity, and a decrease in the
prevalence of Helicobacter pylori infection.6–8 However, the most
recognised risk factor for AC is Barrett’s oesophagus (BO).
BO is a condition in which the squamous epithelium of the
oesophagus is replaced by columnar lined epithelium,
containing specialised intestinal metaplasia with the pre-
sence of goblet cells.9 This replacement is probably a
consequence of prolonged reflux of gastric contents into the
lower oesophagus. It is estimated that BO increases the risk
of AC by approximately 30–125-fold.10 11
As most, if not all, ACs of the oesophagus are preceded by
BO,12 it is suspected that the increase in incidence of AC is
caused by an increase in the incidence of BO. However,
epidemiological data on the incidence of BO in the general
population are scarce and conflicting. An increase in the
incidence of BO has been reported but it is unclear whether
this reflects a true rise in occurrence or an increase in the
diagnosis of BO because of more upper gastrointestinal
endoscopies being performed and/or increased alertness.13 14
This study aimed to investigate the changes in incidence of
diagnosed BO in relation to the number of upper gastro-
intestinal endoscopies, using a unique population based
general practice research database containing detailed
medical data on more than half a million patients.
METHODS
Setting
The Integrated Primary Care Information (IPCI) database is a
general practitioner research database, presently containing
more than 500 000 computer based patient records, obtained
from and maintained by 151 general practitioners in the
Netherlands. This dynamic database was started in 1992 and
has expanded since. The IPCI population has the same sex
and age distribution as the Dutch population. The database is
maintained by the Department of Medical Informatics of the
Erasmus MC, University Medical Centre, Rotterdam, the
Netherlands.
In the Dutch health care system, almost all citizens are
registered with a general practitioner practice and a general
practitioner acts as a gatekeeper to, and as a central receiver
of information from, secondary care. The medical records
from each individual patient can therefore be assumed to
contain all relevant medical information about that person.
The electronic records of the IPCI database contain
anonymous demographic information as well as information
about symptoms and diagnoses (using the International
Classification for Primary Care (ICPC)15 and free text), drug
prescriptions with ICPC coded indications and dosage regi-
mens, referrals to secondary care, laboratory values, mea-
surements such as blood pressure and cholesterol levels, and
hospitalisations. Summaries of hospital discharge letters or
information from specialists are included as free text and
Abbreviations: BO, Barrett’s oesophagus; AC, adenocarcinoma; IPCI,
Integrated Primary Care Information; ICPC, International Classification
for Primary Care
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copies can be provided on request. In order to ensure
completeness of the data, participating general practitioners
are not allowed to use additional paper based medical
records.
The IPCI database complies with European Union guide-
lines on the use of medical data for medical research and has
been proven valid for pharmacoepidemiological research.
Extended details on the database have been described
elsewhere.16 The Scientific and Ethical Advisory Board of
the IPCI project approved the study.
Study population
We included all patients contributing data to the database
between January 1996 and December 2003. One year of
database history was required to be able to describe the
patient’s medical history, and discriminate between prevalent
and incident cases of BO. Follow up started on 1 January
1996 or on the date that one year of valid history was
available, whichever was latest. Follow up ended on the date
of transferring out of the general practitioner practice, last
data obtained from the general practitioner, death of the
patient, occurrence of the specific study outcome (BO or AC),
or 31 December 2003, whichever came first.
Identification and validation of Barrett’s oesophagus
The ICPC does not include a diagnosis code for BO. Therefore,
we applied a sensitive search algorithm to the free text of
each electronic medical record using the Dutch version of the
words ‘‘Barrett’’, ‘‘intestinal metaplasia’’, and ‘‘columnar
epithelium’’ (including obvious misspellings and abbrevia-
tions). Each patient record containing one or more of these
words was reviewed manually by the primary researcher (ES)
and a gastroenterologist (PS) to confirm or reject a diagnosis
of BO. Cases were considered as definite if the record stated
that the patient had BO and contained results from
oesophageal biopsies in which intestinal metaplasia was
confirmed. Patients were defined as possible cases if the
record stated that the patient had BO and contained
additional information making this diagnosis likely, such as
notifications of performed surveillance endoscopies or length
of the BO segment, but no pathological report was entered.
For possible cases, specialist letters including pathological
reports were requested from the general practitioners.
All records of BO patients were reviewed to assess the date
of first diagnosis of BO. Cases were considered as incident
cases if the date of diagnosis fell after inclusion of the patient
in the study cohort. Patients with a diagnosis of BO prior to
study entry were classified as prevalent BO cases and were
not evaluated further.
Upper gastrointestinal endoscopies
In order to identify upper gastrointestinal endoscopies, we
performed an extended computerised database search within
the free text of the medical records using the Dutch version of
the word ‘‘scopy’’ and combinations of words used in the
records to indicate referrals for endoscopy, gastroenterolo-
gists, and gastrointestinal diagnoses. We automatically
removed negations.
Upper gastrointestinal endoscopies were electronically
categorised as valid if the record included information
retrieved from specialist letters containing diagnoses that
can only be confirmed by upper gastrointestinal endoscopy.
Records with possible upper gastrointestinal endoscopies
were reviewed manually and classified as valid or not valid.
We did not count referrals for upper gastrointestinal
endoscopy if they did not have a subsequent recording of
results or a change in medication for an upper gastrointest-
inal tract disorder within a few months after referral. This
was based on the experience that a substantial proportion of
patients with a referral for gastrointestinal endoscopy do not
show up because of fear or because of disappearance of
symptoms. Upper gastrointestinal endoscopies performed
after the date of diagnosis of BO or oesophageal AC were
not taken into account, thereby excluding surveillance and
control endoscopies for BO or AC. To prevent overestimation
of the number of upper gastrointestinal endoscopies at which
BO could be detected (for example, in the case where several
endoscopies were performed during one hospitalisation for
upper gastrointestinal problems), we excluded upper gastro-
intestinal endoscopies performed within three months of the
previous one.
Identification and validation of oesophageal
adenocarcinoma
We included all patients with ICPC codes D77.1 (malignant
neoplasia of the oesophagus) and D77.0 (malignant neopla-
sia of the tractus digestivus—not specified) for further
evaluation. In addition, we applied a search algorithm to
the free text of each electric medical record using com-
binations of the Dutch versions of the words oesophagus,
cancer, carcinoma, malignancy, and neoplasia. All obtained
records were reviewed manually for the presence of
carcinoma in the oesophagus, type of carcinoma (squamous
cell, adeno, or other carcinoma) and date of diagnosis. Cases
Table 1 Incidence of Barrett’s oesophagus (BO) by calendar year, sex, and age category*
No of BO
cases
No of
person years
No of upper GI
endoscopies
BO/100 000
person years
(95% CI)
BO/1000 upper
GI endoscopies
(95% CI)
Overall 260 1 314 933 8495 19.8 (17.5–22.3) 30.6 (27.1–34.5)
1996 7 64 972 421 10.8 (4.8–21.2) 16.6 (7.4–32.6)
1997 17 118 953 858 14.3 (8.6–22.4) 19.8 (12.0–31.0)
1998 27 162 271 1148 16.6 (11.2–23.8) 23.5 (15.8–33.7)
1999 45 218 630 1483 20.6 (15.2–27.3) 30.3 (22.4–40.2)
2000 43 224 570 1384 19.2 (14.1–25.5) 31.1 (22.8–41.4)
2001 48 207 932 1338 23.1 (17.2–30.3) 35.9 (26.8–47.1)
2002 46 198 754 1136 23.1 (17.2–30.6) 40.5 (30.0–53.5)
2003 27 118 853 727 22.7 (15.3–32.6) 37.1 (25.0–53.2)
Sex
Men 158 652 310 3952 24.2 (20.7–28.2) 40.0 (34.1–46.6)
Women 102 662 623 4543 15.4 (12.6–18.6) 22.5 (18.4–27.1)
Age at diagnosis (y)
,40 17 717 690 1858 2.4 (1.4–3.7) 9.2 (5.5–14.3)
40–60 104 383 016 3487 27.2 (22.3–32.8) 29.8 (24.5–36.0)
.60 139 214 228 3150 64.9 (54.8–76.4) 44.1 (37.2–51.9)
GI, gastrointestinal; 95% CI, 95% confidence interval.
*Non-overlapping confidence intervals indicate p,0.05.
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were considered incident cases of AC if the date of diagnosis
fell after the patient was included in the study cohort.
Statistical analyses
The incidence of BO and AC was calculated by dividing the
total number of incident cases of BO or AC by the total
number of person years at risk accumulated by the study
population. The incidence of BO in relation to the number of
upper gastrointestinal endoscopies performed was calculated
by dividing the total number of incident cases of BO by the
total number of upper gastrointestinal endoscopies per-
formed in the study population.
Incidence rates were calculated by sex and age category;
95% confidence intervals (95% CI) were calculated based on a
normal distribution. In order to examine the trends over
time, we excluded the first (1996) and last (2003) year of the
study period because of relatively incomplete follow up.
Linear regression analyses were used to estimate time trends.
A three year moving average was calculated to graph the
age and sex specific incidence rates over calendar time. In
this calculation, the point estimate for one year is the average
of the previous year, the present year, and the following year.
R squared values (r2) were fitted using the method of least
squares to identify time trends and to measure the appro-
priateness of fitting to a linear model. A value of 1 indicates a
perfect linear fit.
Differences between groups were tested using the
Student’s t test in the case of continuous variables after
checking for normal distribution, and by the x2 test in the
case of categorical variables.
The 10 year risk of developing BO was calculated from age
specific BO incidence rates that were adjusted for survival
probability. Mortality data (2000) from which we calculated
survival probability17 were obtained from the Dutch Central
Bureau of Statistics.18 19
RESULTS
The total study cohort comprised 386 002 patients who
contributed a total of 1 316 232 person years of follow up
during the study period (mean 3.4 years per person). Fifty
per cent were male and mean age at the start of follow up
was 35.5 (21.9) years.
The broad computerised search algorithm identified 2542
patients, 491 of whom were classified as definite (40%) or
possible (60%) BO cases after manual review of their medical
records. The proportion of possible cases was constant over
the calendar years. Two hundred and seventy seven of these
cases (56%) were incident. After requesting additional
information, 138 incident cases with histological confirma-
tion and 122 incident cases without histological confirmation
available were included in the analyses.
There were more male (61%) than female BO patients
(p,0.01). Mean age at diagnosis was lower in men than in
women (59.3 (13.8) v 65.5 (15.0) years; p,0.01). The overall
incidence of diagnosed BO was 19.8/100 000 person years
(95% CI 17.5–22.3) and was significantly higher in men than
in women (table 1).
The incidence of BO increased with age (r2 = 0.98; table 1)
and over calendar time from 14.3/100 000 person years in
1997 (95% CI 8.6–22.4) to 23.1 (95% CI 17.2–30.6) in 2002
(r2 = 0.87). The linear trend over time was significant
(p,0.05). Restricting the analyses to histologically confirmed
cases only, the incidence increased from 6.7/100 000 person
years (95% CI 3.2–12.7) in 1997 to 12.6 (95% CI 8.3–18.3) in
2002 (r2 = 0.78; linear trend p,0.05).
Figure 1 shows the 10 year risk of being diagnosed with BO
for symptom free persons at a certain age. For a person of
50 years, the risk of being diagnosed with BO over the next
10 years, when alive, was 0.3%.
Our computerised search for upper gastrointestinal endos-
copies identified 13 965 patients with at least one possible
upper gastrointestinal endoscopy during the study period.
After the electronic validation algorithm and manual review,
a total of 10 435 upper gastrointestinal endoscopies were
identified in 7654 patients over the eight year period. After
exclusion of 491 control or surveillance endoscopies for BO or
AC and 1449 upper gastrointestinal endoscopies performed
within three months of the previous one, 8495 upper
gastrointestinal endoscopies were included for the analyses.
Overall, the number of performed upper gastrointestinal
endoscopies was 6.5/1000 person years (95% CI 6.3–6.6). The
number of upper gastrointestinal endoscopies was signifi-
cantly higher among women than men (6.9/1000 person
years (95%CI 6.7–7.1) v 6.1/1000 person years (95% CI 5.9–
6.2)) and increased with age from 2.6/1000 person years (95%
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Figure 1 Age related risk for a person to be diagnosed with Barrett’s
oesophagus over the coming 10 years.
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Figure 2 Incidence of Barrett’s oesophagus per 1000 upper
gastrointestinal endoscopies over calendar time, with upper and lower
confidence intervals (CI).
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CI 2.5–2.7) for those aged ,40 years to 14.7/1000 person
years (95% CI 14.2–15.2) for patients .60 years (r2 = 1.00).
Over calendar time the number of upper gastrointestinal
endoscopies decreased significantly from 7.2/1000 person
years (95% CI 6.7–7.7) in 1997 to 5.7/1000 person years (95%
CI 5.4–6.1) in 2002 (r2 = 0.52; linear trend p,0.05).
As shown in fig 2, the incidence of BO per 1000 upper
gastrointestinal endoscopies increased linearly from 19.8
(95% CI 12.0–31.0) in 1997 to 40.5 (95% CI 30.0–53.5) in
2002 (r2 = 0.93; linear trend p,0.05). Restricting the analyses
to histologically confirmed cases only, the incidence
increased from 9.3/1000 upper gastrointestinal endoscopies
(95% CI 4.4–17.6) in 1997 to 22.0 (95% CI 14.6–32.0) in 2002
(r2 = 0.85; linear trend p,0.05).
The increase in incidence per 1000 upper gastrointestinal
endoscopies was most pronounced for men ,60 years of age,
rising from 21.3 (95% CI 8.8–43.9) in 1997 to 63.1 (95% CI
40.2–94.6) in 2002 (r2 = 0.85; linear trend p,0.05). The
incidence of BO per 1000 upper gastrointestinal endoscopies
for women .60 years of age was also noted to be rising, from
24.0 (95% CI 8.0–56.9) in 1997 to 35.2 (95% CI 16.6–66.5) in
2002, but this was less consistent with a linear line (r2 = 0.47;
linear trend p = 0.06) and only based on small numbers.
Figure 3 shows the three year moving average age and sex
specific incidence rates of BO over calendar time.
We identified 51 patients diagnosed with AC between 1996
and 2003, 39 (76%) of whom were male. Mean age at
diagnosis was lower in men than in women (66.3 (10.2) v
72.3 (5.4); p,0.05). The overall incidence was 3.9/100 000
person years (95% CI 2.9–5.1). The incidence increased over
calendar time from 1.7/100 000 person years (95% CI 0.3–5.4)
in 1997 to 6.0 (95% CI 3.3–10.2) in 2002 (r2 = 0.87; linear
trend p,0.05).
Seven of the incident AC cases (14%) had a diagnosis of BO
more than one year before the diagnosis of AC. Seven other
AC patients (14%) were diagnosed with BO at the time that
they were diagnosed with AC (between three months before
and three months after the date of diagnosis of AC). The
remaining cases had no evidence of BO recorded before or at
the date of diagnosis of AC.
DISCUSSION
In this study, we observed a linear increase in the incidence
of diagnosed BO in the general population, from 14.3/100 000
person years in 1997 to 23.1/100 000 person years in 2002. If
the incidence was based on the number of upper gastro-
intestinal endoscopies performed in the same period, the
increase was even more pronounced, from 19.8/1000 upper
gastrointestinal endoscopies in 1997 to 40.5/1000 upper
gastrointestinal endoscopies in 2002 (fig 2). The incidence
of AC increased in the same period, from 1.7/100 000 to 6.0/
100 000 person years.
To our knowledge, only two reports have studied time
trends for the incidence of BO at the population level. The
conclusions of these studies were conflicting. Prach and
colleagues13 showed an increase in incidence from 1.4 new
cases of BO per 1000 upper gastrointestinal endoscopies in
1980–1981 to 42.7 new cases of BO per 1000 upper
gastrointestinal endoscopies in 1992–1993 in Scotland. They
believed their results reflected a true rise in incidence of BO.
Conio and colleagues14 also observed a strong increase in the
incidence of BO per 100 000 person years in Minnesota but a
similar increase in the number of upper gastrointestinal
endoscopies was noted over the same time period. They
concluded that the increase in incidence of BO in their study
reflected a rise in upper gastrointestinal endoscopies
performed instead of a true increase in BO.
The main risk factor for BO is gastro-oesophageal reflux
disease. The frequency, severity, and duration of acid reflux
are positively associated with BO.20 21 It has been estimated
that approximately 20% of the general population experience
reflux symptoms on at least a weekly basis22 and the
incidence of reflux oesophagitis is increasing over time.23 It
has been suggested that the incidence of gastro-oesophageal
reflux disease is linked with an increasing average body
weight,24 and with an increasing average body height in
association with a decreasing prevalence of Helicobacter pylori
infection in the population.25
The rise in incidence of BO that we observed was most
pronounced in men less than 60 years of age (fig 3). A
possible explanation could be that men are now exposed to
risk factors for BO at a younger age than they were in the
past. Obesity could play a role in this regard. However,
obesity at a younger age is also increasing among women,
thereby leaving room for other unidentified risk or protective
factors for BO.
The observed decline in the number of upper gastrointest-
inal endoscopies performed per capita in our study is likely to
be explained by the introduction of the first general
practitioner guidelines on dyspepsia in the Netherlands in
1993, with a revision in 1996.26 27 These guidelines advised
restrictions in referrals for upper gastrointestinal endoscopy
in the case of dyspepsia in the absence of alarm symptoms.
Incidence studies conducted with computerised medical
records have a risk of misclassification. To limit under-
estimation we used broad search criteria in free text and
manually validated all retrieved records. However, patholo-
gical reports on the presence of intestinal metaplasia in the
BO segment were not available for all BO patients, even after
requesting additional information from general practitioners.
Restricting our analyses to only histologically confirmed cases
did not however change the observed increasing trend over
time.
The reliability of our observed number of upper gastro-
intestinal endoscopies performed is supported by the similar
results of a previous nationwide survey by the Dutch
Gastroenterology Association, which reported a total of
130 000 upper gastrointestinal endoscopies performed in
2000 in the Netherlands, equalling approximately 8.1/1000
person years.28 As we excluded control and surveillance
endoscopies for BO or AC, and also upper gastrointestinal
endoscopies performed within three months of the previous
one, we feel that our results truly reflect clinical practice in
the area under study.
We repeated our analyses including all upper gastrointest-
inal endoscopies performed within three months of the
previous one to assess if this modification changed our
results. The incidence of BO per 1000 upper gastrointestinal
endoscopies was somewhat lower than in our original
analyses but both lines were parallel, indicating a similar
increase in incidence of BO over time (data not shown).
It is well known that not all BO patients have reflux
symptoms.29–31 As a consequence, most of these patients will
not undergo upper gastrointestinal endoscopy and cases will
be missed. A study by Cameron and colleagues32 showed a
21-fold higher number of cases of BO based on autopsy
findings than was actually seen in the population. This
clearly illustrates the magnitude of the potential under-
estimation of BO in the general population. We assume that
such under detection of BO was present in our study also,
implying that the actual incidence rate of BO could be
considerably higher than that found in our study. However,
there is no reason to believe that the degree of this
underestimation has changed over time.
The increased incidence of BO over time may partly have
resulted from an increased awareness and the improved skills
of endoscopists in diagnosing the presence of Barrett’s
mucosa. If this is the case, then the observed increase in
Incidence of Barrett’s oesophagus in the general population 1065
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incidence of BO would, at least in part, be due to a higher
detection rate of Barrett’s patients, instead of a real rise in
incidence. The distinction between long and short segment
Barrett’s might provide further insight as the observer
variability is expected to be lower in long segment BO.
Unfortunately, such a distinction is not possible in our
database. However, the differing trend in incidence between
age groups (fig 3) does not support the explanation that the
increasing incidence is only secondary to an increased
awareness or a change in diagnostic criteria. If increased
awareness is solely responsible for the increase in incidence
we observed, we would expect similar time trends in the
different age groups, and for males and females.
It is likely that the number of patients with AC reported
here is underestimated as we excluded patients with
oesophageal cancer of unknown type (n = 23). Including
these patients did not change the trend over time (data not
shown). As differentiation between oesophageal cancer and
cancer of the gastric cardia, which we did not include, is
difficult, it is possible that some additional cases were
missed.
Estimates for the incidence of AC were based on small
numbers and had wide confidence intervals. Despite the fact
that chance may explain at least some of our results, another
study in the Netherlands, based on the Dutch Cancer
Registry, showed an increase of similar magnitude in the
incidence of AC over a six year period preceding our study
(1990–1996).33
It seems that the increase in incidence of AC between 1997
and 2002 was greater than the increase in incidence of BO
over the same period. As it is generally expected that
progression from BO to AC takes several years, it may be
that the incidence trend for AC in this study reflects the
incidence trend for BO from several years ago and the
increase in incidence of BO is slowing down at present. It is
also possible that the rising incidence of BO is not solely
responsible for the increase in incidence of AC. Other factors
may also be important such as those influencing the rate of
malignant progression from BO to AC.
In conclusion, our results showed an increase in the
incidence of detected BO, which cannot be explained by a rise
in the number of upper gastrointestinal endoscopies per-
formed. The cause of this increase and its implications
require further study but it is likely that a further increase in
the incidence of BO carcinomas in the coming decade will
occur.
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